nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—FMO1—Cimetidine—obesity	0.233	0.483	CbGbCtD
Vandetanib—FMO3—Cimetidine—obesity	0.146	0.302	CbGbCtD
Vandetanib—ORM1—Bupropion—obesity	0.0591	0.122	CbGbCtD
Vandetanib—ALB—obesity	0.0438	1	CbGaD
Vandetanib—CYP3A4—Sibutramine—obesity	0.0121	0.025	CbGbCtD
Vandetanib—CYP3A4—Benzphetamine—obesity	0.00916	0.019	CbGbCtD
Vandetanib—CYP3A4—Bupropion—obesity	0.00779	0.0161	CbGbCtD
Vandetanib—BMPR1B—ovarian follicle—obesity	0.00723	0.0656	CbGeAlD
Vandetanib—CYP3A4—Orlistat—obesity	0.00635	0.0131	CbGbCtD
Vandetanib—CYP3A4—Cimetidine—obesity	0.00572	0.0118	CbGbCtD
Vandetanib—CYP3A4—Topiramate—obesity	0.00374	0.00774	CbGbCtD
Vandetanib—RET—autonomic nervous system—obesity	0.00258	0.0234	CbGeAlD
Vandetanib—ORM1—bile—obesity	0.00234	0.0212	CbGeAlD
Vandetanib—Erlotinib—NR1I2—obesity	0.00138	0.447	CrCbGaD
Vandetanib—STK35—hindbrain—obesity	0.00133	0.0121	CbGeAlD
Vandetanib—Bosutinib—RPS6KB1—obesity	0.00132	0.427	CrCbGaD
Vandetanib—PLK4—respiratory system—obesity	0.00104	0.00941	CbGeAlD
Vandetanib—FYN—hindbrain—obesity	0.00101	0.0092	CbGeAlD
Vandetanib—MAP3K19—respiratory system—obesity	0.000955	0.00866	CbGeAlD
Vandetanib—STK35—islet of Langerhans—obesity	0.00086	0.00779	CbGeAlD
Vandetanib—FLT3—respiratory system—obesity	0.000829	0.00751	CbGeAlD
Vandetanib—MAP2K5—hindbrain—obesity	0.00081	0.00734	CbGeAlD
Vandetanib—BLK—adrenal gland—obesity	0.000805	0.0073	CbGeAlD
Vandetanib—PTK6—digestive system—obesity	0.000801	0.00726	CbGeAlD
Vandetanib—RIPK2—islet of Langerhans—obesity	0.000793	0.00719	CbGeAlD
Vandetanib—VEGFA—islet of Langerhans—obesity	0.000791	0.00717	CbGeAlD
Vandetanib—IRAK4—islet of Langerhans—obesity	0.000774	0.00702	CbGeAlD
Vandetanib—FLT4—respiratory system—obesity	0.000753	0.00682	CbGeAlD
Vandetanib—ERBB3—respiratory system—obesity	0.000716	0.0065	CbGeAlD
Vandetanib—PDGFRB—gall bladder—obesity	0.000692	0.00627	CbGeAlD
Vandetanib—SLK—islet of Langerhans—obesity	0.000675	0.00612	CbGeAlD
Vandetanib—FGR—respiratory system—obesity	0.000664	0.00602	CbGeAlD
Vandetanib—PTK6—endocrine gland—obesity	0.000662	0.006	CbGeAlD
Vandetanib—AXL—respiratory system—obesity	0.000662	0.006	CbGeAlD
Vandetanib—EPHA5—pituitary gland—obesity	0.000661	0.00599	CbGeAlD
Vandetanib—ORM1—gall bladder—obesity	0.000649	0.00588	CbGeAlD
Vandetanib—BMPR1B—adipose tissue—obesity	0.000645	0.00585	CbGeAlD
Vandetanib—FMO3—respiratory system—obesity	0.000642	0.00582	CbGeAlD
Vandetanib—MAP4K5—islet of Langerhans—obesity	0.000641	0.00581	CbGeAlD
Vandetanib—FLT3—cardiovascular system—obesity	0.000635	0.00575	CbGeAlD
Vandetanib—FLT4—adrenal cortex—obesity	0.000632	0.00573	CbGeAlD
Vandetanib—PLK4—adrenal gland—obesity	0.000628	0.0057	CbGeAlD
Vandetanib—VEGFA—adrenal cortex—obesity	0.000626	0.00568	CbGeAlD
Vandetanib—ABL1—hindbrain—obesity	0.000625	0.00567	CbGeAlD
Vandetanib—EPHA5—digestive system—obesity	0.00062	0.00562	CbGeAlD
Vandetanib—FYN—respiratory system—obesity	0.000619	0.00562	CbGeAlD
Vandetanib—IRAK4—adrenal cortex—obesity	0.000613	0.00556	CbGeAlD
Vandetanib—EPHB6—islet of Langerhans—obesity	0.000613	0.00555	CbGeAlD
Vandetanib—TEK—respiratory system—obesity	0.000605	0.00549	CbGeAlD
Vandetanib—YES1—islet of Langerhans—obesity	0.000592	0.00537	CbGeAlD
Vandetanib—BMPR1B—adrenal gland—obesity	0.000578	0.00524	CbGeAlD
Vandetanib—FLT4—cardiovascular system—obesity	0.000576	0.00523	CbGeAlD
Vandetanib—RIPK2—cardiovascular system—obesity	0.000573	0.0052	CbGeAlD
Vandetanib—SRC—islet of Langerhans—obesity	0.000569	0.00516	CbGeAlD
Vandetanib—ALB—gall bladder—obesity	0.000569	0.00516	CbGeAlD
Vandetanib—MKNK1—adrenal cortex—obesity	0.000565	0.00512	CbGeAlD
Vandetanib—YES1—respiratory system—obesity	0.000559	0.00507	CbGeAlD
Vandetanib—AXL—adrenal cortex—obesity	0.000555	0.00504	CbGeAlD
Vandetanib—STK10—respiratory system—obesity	0.000554	0.00502	CbGeAlD
Vandetanib—EPHA6—endocrine gland—obesity	0.000552	0.005	CbGeAlD
Vandetanib—STK35—adipose tissue—obesity	0.000548	0.00497	CbGeAlD
Vandetanib—PLK4—endocrine gland—obesity	0.000545	0.00494	CbGeAlD
Vandetanib—FMO3—adrenal cortex—obesity	0.000539	0.00488	CbGeAlD
Vandetanib—SRC—respiratory system—obesity	0.000538	0.00488	CbGeAlD
Vandetanib—ABL2—pituitary gland—obesity	0.000536	0.00486	CbGeAlD
Vandetanib—SLK—adrenal cortex—obesity	0.000535	0.00485	CbGeAlD
Vandetanib—ABL2—adipose tissue—obesity	0.000534	0.00484	CbGeAlD
Vandetanib—EGFR—adipose tissue—obesity	0.000522	0.00473	CbGeAlD
Vandetanib—MKNK1—cardiovascular system—obesity	0.000515	0.00467	CbGeAlD
Vandetanib—TYRO3—endocrine gland—obesity	0.000512	0.00464	CbGeAlD
Vandetanib—EPHA5—endocrine gland—obesity	0.000512	0.00464	CbGeAlD
Vandetanib—LYN—endocrine gland—obesity	0.000509	0.00462	CbGeAlD
Vandetanib—FGR—cardiovascular system—obesity	0.000509	0.00461	CbGeAlD
Vandetanib—FLT4—adipose tissue—obesity	0.000508	0.00461	CbGeAlD
Vandetanib—TEK—adrenal cortex—obesity	0.000508	0.00461	CbGeAlD
Vandetanib—RIPK2—pituitary gland—obesity	0.000508	0.0046	CbGeAlD
Vandetanib—AXL—cardiovascular system—obesity	0.000507	0.0046	CbGeAlD
Vandetanib—VEGFA—pituitary gland—obesity	0.000506	0.00459	CbGeAlD
Vandetanib—RIPK2—adipose tissue—obesity	0.000506	0.00458	CbGeAlD
Vandetanib—VEGFA—adipose tissue—obesity	0.000504	0.00457	CbGeAlD
Vandetanib—FMO1—pituitary gland—obesity	0.000504	0.00457	CbGeAlD
Vandetanib—FLT3—adrenal gland—obesity	0.000502	0.00455	CbGeAlD
Vandetanib—BMPR1B—endocrine gland—obesity	0.000502	0.00455	CbGeAlD
Vandetanib—FMO1—adipose tissue—obesity	0.000501	0.00455	CbGeAlD
Vandetanib—IRAK4—pituitary gland—obesity	0.000496	0.00449	CbGeAlD
Vandetanib—KDR—respiratory system—obesity	0.000495	0.00449	CbGeAlD
Vandetanib—IRAK4—adipose tissue—obesity	0.000494	0.00448	CbGeAlD
Vandetanib—STK35—adrenal gland—obesity	0.000492	0.00446	CbGeAlD
Vandetanib—ERBB3—adipose tissue—obesity	0.000484	0.00439	CbGeAlD
Vandetanib—ABL2—adrenal gland—obesity	0.000479	0.00435	CbGeAlD
Vandetanib—RIPK2—digestive system—obesity	0.000476	0.00431	CbGeAlD
Vandetanib—FYN—cardiovascular system—obesity	0.000474	0.0043	CbGeAlD
Vandetanib—FMO1—digestive system—obesity	0.000472	0.00428	CbGeAlD
Vandetanib—YES1—adrenal cortex—obesity	0.000469	0.00425	CbGeAlD
Vandetanib—EGFR—adrenal gland—obesity	0.000468	0.00424	CbGeAlD
Vandetanib—TEK—cardiovascular system—obesity	0.000464	0.0042	CbGeAlD
Vandetanib—LYN—liver—obesity	0.000459	0.00416	CbGeAlD
Vandetanib—MKNK1—pituitary gland—obesity	0.000456	0.00414	CbGeAlD
Vandetanib—FLT4—adrenal gland—obesity	0.000456	0.00413	CbGeAlD
Vandetanib—ERBB3—digestive system—obesity	0.000456	0.00413	CbGeAlD
Vandetanib—MKNK1—adipose tissue—obesity	0.000454	0.00412	CbGeAlD
Vandetanib—RIPK2—adrenal gland—obesity	0.000453	0.00411	CbGeAlD
Vandetanib—PDGFRB—islet of Langerhans—obesity	0.000453	0.00411	CbGeAlD
Vandetanib—VEGFA—adrenal gland—obesity	0.000452	0.0041	CbGeAlD
Vandetanib—FGR—pituitary gland—obesity	0.000451	0.00409	CbGeAlD
Vandetanib—RET—pituitary gland—obesity	0.000451	0.00409	CbGeAlD
Vandetanib—FMO1—adrenal gland—obesity	0.00045	0.00408	CbGeAlD
Vandetanib—AXL—pituitary gland—obesity	0.000449	0.00407	CbGeAlD
Vandetanib—LCK—adipose tissue—obesity	0.000449	0.00407	CbGeAlD
Vandetanib—FGR—adipose tissue—obesity	0.000449	0.00407	CbGeAlD
Vandetanib—AXL—adipose tissue—obesity	0.000447	0.00405	CbGeAlD
Vandetanib—IRAK4—adrenal gland—obesity	0.000443	0.00401	CbGeAlD
Vandetanib—FLT3—endocrine gland—obesity	0.000435	0.00395	CbGeAlD
Vandetanib—FMO3—pituitary gland—obesity	0.000435	0.00395	CbGeAlD
Vandetanib—FMO3—adipose tissue—obesity	0.000433	0.00393	CbGeAlD
Vandetanib—SLK—pituitary gland—obesity	0.000432	0.00392	CbGeAlD
Vandetanib—SLK—adipose tissue—obesity	0.00043	0.0039	CbGeAlD
Vandetanib—PDGFRB—respiratory system—obesity	0.000428	0.00388	CbGeAlD
Vandetanib—MKNK1—digestive system—obesity	0.000428	0.00388	CbGeAlD
Vandetanib—STK35—endocrine gland—obesity	0.000426	0.00387	CbGeAlD
Vandetanib—STK10—cardiovascular system—obesity	0.000424	0.00385	CbGeAlD
Vandetanib—FGR—digestive system—obesity	0.000422	0.00383	CbGeAlD
Vandetanib—RET—digestive system—obesity	0.000422	0.00383	CbGeAlD
Vandetanib—FYN—pituitary gland—obesity	0.00042	0.00381	CbGeAlD
Vandetanib—FYN—adipose tissue—obesity	0.000418	0.00379	CbGeAlD
Vandetanib—KDR—adrenal cortex—obesity	0.000415	0.00376	CbGeAlD
Vandetanib—MAP2K5—adrenal cortex—obesity	0.000415	0.00376	CbGeAlD
Vandetanib—SRC—cardiovascular system—obesity	0.000412	0.00373	CbGeAlD
Vandetanib—MAP4K5—pituitary gland—obesity	0.00041	0.00372	CbGeAlD
Vandetanib—TEK—pituitary gland—obesity	0.00041	0.00372	CbGeAlD
Vandetanib—MAP4K5—adipose tissue—obesity	0.000409	0.00371	CbGeAlD
Vandetanib—TEK—adipose tissue—obesity	0.000409	0.00371	CbGeAlD
Vandetanib—MKNK1—adrenal gland—obesity	0.000408	0.00369	CbGeAlD
Vandetanib—ABL1—islet of Langerhans—obesity	0.000404	0.00366	CbGeAlD
Vandetanib—LCK—adrenal gland—obesity	0.000403	0.00365	CbGeAlD
Vandetanib—FGR—adrenal gland—obesity	0.000403	0.00365	CbGeAlD
Vandetanib—RET—adrenal gland—obesity	0.000403	0.00365	CbGeAlD
Vandetanib—AXL—adrenal gland—obesity	0.000401	0.00363	CbGeAlD
Vandetanib—FLT4—endocrine gland—obesity	0.000395	0.00358	CbGeAlD
Vandetanib—FYN—digestive system—obesity	0.000394	0.00357	CbGeAlD
Vandetanib—RIPK2—endocrine gland—obesity	0.000393	0.00357	CbGeAlD
Vandetanib—FLT3—liver—obesity	0.000392	0.00356	CbGeAlD
Vandetanib—EPHB6—pituitary gland—obesity	0.000392	0.00356	CbGeAlD
Vandetanib—EPHB6—adipose tissue—obesity	0.000391	0.00354	CbGeAlD
Vandetanib—FMO1—endocrine gland—obesity	0.00039	0.00354	CbGeAlD
Vandetanib—FMO3—adrenal gland—obesity	0.000389	0.00352	CbGeAlD
Vandetanib—SLK—adrenal gland—obesity	0.000386	0.0035	CbGeAlD
Vandetanib—STK35—liver—obesity	0.000385	0.00349	CbGeAlD
Vandetanib—ABL1—respiratory system—obesity	0.000382	0.00346	CbGeAlD
Vandetanib—YES1—pituitary gland—obesity	0.000379	0.00344	CbGeAlD
Vandetanib—MAP2K5—cardiovascular system—obesity	0.000379	0.00344	CbGeAlD
Vandetanib—KDR—cardiovascular system—obesity	0.000379	0.00344	CbGeAlD
Vandetanib—YES1—adipose tissue—obesity	0.000378	0.00342	CbGeAlD
Vandetanib—ERBB3—endocrine gland—obesity	0.000376	0.00341	CbGeAlD
Vandetanib—FYN—adrenal gland—obesity	0.000375	0.0034	CbGeAlD
Vandetanib—ABL2—liver—obesity	0.000375	0.0034	CbGeAlD
Vandetanib—STK10—adipose tissue—obesity	0.000374	0.00339	CbGeAlD
Vandetanib—MAP4K5—adrenal gland—obesity	0.000367	0.00332	CbGeAlD
Vandetanib—TEK—adrenal gland—obesity	0.000367	0.00332	CbGeAlD
Vandetanib—EGFR—liver—obesity	0.000366	0.00332	CbGeAlD
Vandetanib—SRC—adipose tissue—obesity	0.000363	0.00329	CbGeAlD
Vandetanib—PDGFRB—adrenal cortex—obesity	0.000359	0.00326	CbGeAlD
Vandetanib—FLT4—liver—obesity	0.000356	0.00323	CbGeAlD
Vandetanib—YES1—digestive system—obesity	0.000355	0.00322	CbGeAlD
Vandetanib—RIPK2—liver—obesity	0.000355	0.00321	CbGeAlD
Vandetanib—VEGFA—liver—obesity	0.000354	0.00321	CbGeAlD
Vandetanib—MKNK1—endocrine gland—obesity	0.000353	0.0032	CbGeAlD
Vandetanib—STK10—digestive system—obesity	0.000352	0.00319	CbGeAlD
Vandetanib—FMO1—liver—obesity	0.000352	0.00319	CbGeAlD
Vandetanib—EPHB6—adrenal gland—obesity	0.00035	0.00318	CbGeAlD
Vandetanib—RET—endocrine gland—obesity	0.000349	0.00316	CbGeAlD
Vandetanib—FGR—endocrine gland—obesity	0.000349	0.00316	CbGeAlD
Vandetanib—AXL—endocrine gland—obesity	0.000348	0.00315	CbGeAlD
Vandetanib—IRAK4—liver—obesity	0.000346	0.00314	CbGeAlD
Vandetanib—SRC—digestive system—obesity	0.000342	0.0031	CbGeAlD
Vandetanib—ERBB3—liver—obesity	0.000339	0.00308	CbGeAlD
Vandetanib—YES1—adrenal gland—obesity	0.000339	0.00307	CbGeAlD
Vandetanib—FMO3—endocrine gland—obesity	0.000337	0.00306	CbGeAlD
Vandetanib—STK10—adrenal gland—obesity	0.000336	0.00304	CbGeAlD
Vandetanib—KDR—pituitary gland—obesity	0.000335	0.00304	CbGeAlD
Vandetanib—MAP2K5—pituitary gland—obesity	0.000335	0.00304	CbGeAlD
Vandetanib—MAP2K5—adipose tissue—obesity	0.000334	0.00303	CbGeAlD
Vandetanib—KDR—adipose tissue—obesity	0.000334	0.00303	CbGeAlD
Vandetanib—PDGFRB—cardiovascular system—obesity	0.000328	0.00297	CbGeAlD
Vandetanib—SRC—adrenal gland—obesity	0.000326	0.00295	CbGeAlD
Vandetanib—FYN—endocrine gland—obesity	0.000325	0.00295	CbGeAlD
Vandetanib—ABL1—adrenal cortex—obesity	0.00032	0.0029	CbGeAlD
Vandetanib—MKNK1—liver—obesity	0.000319	0.00289	CbGeAlD
Vandetanib—TEK—endocrine gland—obesity	0.000318	0.00288	CbGeAlD
Vandetanib—MAP4K5—endocrine gland—obesity	0.000318	0.00288	CbGeAlD
Vandetanib—LCK—liver—obesity	0.000315	0.00285	CbGeAlD
Vandetanib—FGR—liver—obesity	0.000315	0.00285	CbGeAlD
Vandetanib—KDR—digestive system—obesity	0.000315	0.00285	CbGeAlD
Vandetanib—AXL—liver—obesity	0.000313	0.00284	CbGeAlD
Vandetanib—FMO3—liver—obesity	0.000304	0.00276	CbGeAlD
Vandetanib—SLK—liver—obesity	0.000302	0.00274	CbGeAlD
Vandetanib—KDR—adrenal gland—obesity	0.0003	0.00272	CbGeAlD
Vandetanib—MAP2K5—adrenal gland—obesity	0.0003	0.00272	CbGeAlD
Vandetanib—YES1—endocrine gland—obesity	0.000294	0.00266	CbGeAlD
Vandetanib—FYN—liver—obesity	0.000293	0.00266	CbGeAlD
Vandetanib—ABL1—cardiovascular system—obesity	0.000292	0.00265	CbGeAlD
Vandetanib—STK10—endocrine gland—obesity	0.000291	0.00264	CbGeAlD
Vandetanib—PDGFRB—pituitary gland—obesity	0.00029	0.00263	CbGeAlD
Vandetanib—PDGFRB—adipose tissue—obesity	0.000289	0.00262	CbGeAlD
Vandetanib—MAP4K5—liver—obesity	0.000287	0.0026	CbGeAlD
Vandetanib—TEK—liver—obesity	0.000287	0.0026	CbGeAlD
Vandetanib—SRC—endocrine gland—obesity	0.000283	0.00256	CbGeAlD
Vandetanib—PDGFRB—digestive system—obesity	0.000272	0.00247	CbGeAlD
Vandetanib—YES1—liver—obesity	0.000265	0.0024	CbGeAlD
Vandetanib—STK10—liver—obesity	0.000262	0.00238	CbGeAlD
Vandetanib—MAP2K5—endocrine gland—obesity	0.00026	0.00236	CbGeAlD
Vandetanib—KDR—endocrine gland—obesity	0.00026	0.00236	CbGeAlD
Vandetanib—PDGFRB—adrenal gland—obesity	0.000259	0.00235	CbGeAlD
Vandetanib—ABL1—pituitary gland—obesity	0.000259	0.00235	CbGeAlD
Vandetanib—ABL1—adipose tissue—obesity	0.000258	0.00234	CbGeAlD
Vandetanib—SRC—liver—obesity	0.000255	0.00231	CbGeAlD
Vandetanib—ABCC1—adrenal cortex—obesity	0.000244	0.00221	CbGeAlD
Vandetanib—ABL1—digestive system—obesity	0.000243	0.0022	CbGeAlD
Vandetanib—Erlotinib—ALB—obesity	0.000238	0.0772	CrCbGaD
Vandetanib—MAP2K5—liver—obesity	0.000234	0.00212	CbGeAlD
Vandetanib—KDR—liver—obesity	0.000234	0.00212	CbGeAlD
Vandetanib—ABL1—adrenal gland—obesity	0.000231	0.0021	CbGeAlD
Vandetanib—Bladder pain—Topiramate—obesity	0.000226	0.00137	CcSEcCtD
Vandetanib—Nausea—Phenylpropanolamine—obesity	0.000225	0.00137	CcSEcCtD
Vandetanib—PDGFRB—endocrine gland—obesity	0.000225	0.00204	CbGeAlD
Vandetanib—Photosensitivity reaction—Bupropion—obesity	0.000225	0.00137	CcSEcCtD
Vandetanib—Weight decreased—Bupropion—obesity	0.000223	0.00135	CcSEcCtD
Vandetanib—Hyperglycaemia—Bupropion—obesity	0.000222	0.00135	CcSEcCtD
Vandetanib—Pneumonia—Bupropion—obesity	0.000221	0.00134	CcSEcCtD
Vandetanib—Infestation—Bupropion—obesity	0.000219	0.00134	CcSEcCtD
Vandetanib—Infestation NOS—Bupropion—obesity	0.000219	0.00134	CcSEcCtD
Vandetanib—Visual impairment—Sibutramine—obesity	0.000218	0.00132	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Bupropion—obesity	0.000218	0.00132	CcSEcCtD
Vandetanib—Diarrhoea—Diethylpropion—obesity	0.000216	0.00131	CcSEcCtD
Vandetanib—Nausea—Phentermine—obesity	0.000216	0.00131	CcSEcCtD
Vandetanib—Asthenia—Cimetidine—obesity	0.000216	0.00131	CcSEcCtD
Vandetanib—Stomatitis—Bupropion—obesity	0.000214	0.0013	CcSEcCtD
Vandetanib—ALB—adrenal gland—obesity	0.000213	0.00193	CbGeAlD
Vandetanib—Conjunctivitis—Bupropion—obesity	0.000213	0.0013	CcSEcCtD
Vandetanib—Urinary tract infection—Bupropion—obesity	0.000213	0.0013	CcSEcCtD
Vandetanib—Eye disorder—Sibutramine—obesity	0.000211	0.00128	CcSEcCtD
Vandetanib—ORM1—endocrine gland—obesity	0.000211	0.00191	CbGeAlD
Vandetanib—Mediastinal disorder—Orlistat—obesity	0.00021	0.00128	CcSEcCtD
Vandetanib—Dizziness—Diethylpropion—obesity	0.000209	0.00127	CcSEcCtD
Vandetanib—Epistaxis—Bupropion—obesity	0.000207	0.00126	CcSEcCtD
Vandetanib—Alopecia—Orlistat—obesity	0.000206	0.00126	CcSEcCtD
Vandetanib—Sinusitis—Bupropion—obesity	0.000206	0.00125	CcSEcCtD
Vandetanib—Diarrhoea—Cimetidine—obesity	0.000206	0.00125	CcSEcCtD
Vandetanib—Angiopathy—Sibutramine—obesity	0.000205	0.00125	CcSEcCtD
Vandetanib—Gastroenteritis—Topiramate—obesity	0.000205	0.00125	CcSEcCtD
Vandetanib—Mental disorder—Orlistat—obesity	0.000205	0.00124	CcSEcCtD
Vandetanib—Malnutrition—Orlistat—obesity	0.000203	0.00124	CcSEcCtD
Vandetanib—PDGFRB—liver—obesity	0.000203	0.00184	CbGeAlD
Vandetanib—ABCG2—adrenal cortex—obesity	0.000202	0.00183	CbGeAlD
Vandetanib—Arrhythmia—Sibutramine—obesity	0.000202	0.00123	CcSEcCtD
Vandetanib—Vomiting—Diethylpropion—obesity	0.000201	0.00122	CcSEcCtD
Vandetanib—ABL1—endocrine gland—obesity	0.0002	0.00182	CbGeAlD
Vandetanib—Alopecia—Sibutramine—obesity	0.0002	0.00121	CcSEcCtD
Vandetanib—Rash—Diethylpropion—obesity	0.000199	0.00121	CcSEcCtD
Vandetanib—Dysgeusia—Orlistat—obesity	0.000199	0.00121	CcSEcCtD
Vandetanib—Dermatitis—Diethylpropion—obesity	0.000199	0.00121	CcSEcCtD
Vandetanib—Dizziness—Cimetidine—obesity	0.000199	0.00121	CcSEcCtD
Vandetanib—Haemoglobin—Bupropion—obesity	0.000198	0.0012	CcSEcCtD
Vandetanib—Headache—Diethylpropion—obesity	0.000198	0.0012	CcSEcCtD
Vandetanib—ABCC1—pituitary gland—obesity	0.000197	0.00179	CbGeAlD
Vandetanib—Haemorrhage—Bupropion—obesity	0.000197	0.0012	CcSEcCtD
Vandetanib—Malnutrition—Sibutramine—obesity	0.000197	0.0012	CcSEcCtD
Vandetanib—ABCC1—adipose tissue—obesity	0.000196	0.00178	CbGeAlD
Vandetanib—Muscle spasms—Orlistat—obesity	0.000195	0.00119	CcSEcCtD
Vandetanib—Urinary tract disorder—Bupropion—obesity	0.000195	0.00118	CcSEcCtD
Vandetanib—Urethral disorder—Bupropion—obesity	0.000193	0.00117	CcSEcCtD
Vandetanib—Dysgeusia—Sibutramine—obesity	0.000193	0.00117	CcSEcCtD
Vandetanib—Vision blurred—Orlistat—obesity	0.000192	0.00117	CcSEcCtD
Vandetanib—Vomiting—Cimetidine—obesity	0.000191	0.00116	CcSEcCtD
Vandetanib—ORM1—liver—obesity	0.00019	0.00172	CbGeAlD
Vandetanib—Visual impairment—Bupropion—obesity	0.00019	0.00116	CcSEcCtD
Vandetanib—Rash—Cimetidine—obesity	0.000189	0.00115	CcSEcCtD
Vandetanib—Dermatitis—Cimetidine—obesity	0.000189	0.00115	CcSEcCtD
Vandetanib—Muscle spasms—Sibutramine—obesity	0.000189	0.00115	CcSEcCtD
Vandetanib—Headache—Cimetidine—obesity	0.000188	0.00115	CcSEcCtD
Vandetanib—Nausea—Diethylpropion—obesity	0.000188	0.00114	CcSEcCtD
Vandetanib—Erythema multiforme—Bupropion—obesity	0.000186	0.00113	CcSEcCtD
Vandetanib—Hypoglycaemia—Topiramate—obesity	0.000186	0.00113	CcSEcCtD
Vandetanib—Vision blurred—Sibutramine—obesity	0.000185	0.00113	CcSEcCtD
Vandetanib—Lethargy—Topiramate—obesity	0.000185	0.00113	CcSEcCtD
Vandetanib—Tremor—Sibutramine—obesity	0.000184	0.00112	CcSEcCtD
Vandetanib—Eye disorder—Bupropion—obesity	0.000184	0.00112	CcSEcCtD
Vandetanib—Cardiac disorder—Bupropion—obesity	0.000183	0.00111	CcSEcCtD
Vandetanib—Hyponatraemia—Topiramate—obesity	0.000182	0.00111	CcSEcCtD
Vandetanib—ABL1—liver—obesity	0.000181	0.00164	CbGeAlD
Vandetanib—Angiopathy—Bupropion—obesity	0.000179	0.00109	CcSEcCtD
Vandetanib—Nausea—Cimetidine—obesity	0.000178	0.00109	CcSEcCtD
Vandetanib—Mediastinal disorder—Bupropion—obesity	0.000178	0.00108	CcSEcCtD
Vandetanib—Cough—Orlistat—obesity	0.000177	0.00108	CcSEcCtD
Vandetanib—Convulsion—Orlistat—obesity	0.000176	0.00107	CcSEcCtD
Vandetanib—ABCC1—adrenal gland—obesity	0.000176	0.0016	CbGeAlD
Vandetanib—Arrhythmia—Bupropion—obesity	0.000176	0.00107	CcSEcCtD
Vandetanib—Alopecia—Bupropion—obesity	0.000174	0.00106	CcSEcCtD
Vandetanib—Chest pain—Orlistat—obesity	0.000173	0.00105	CcSEcCtD
Vandetanib—Loss of consciousness—Sibutramine—obesity	0.000173	0.00105	CcSEcCtD
Vandetanib—Mental disorder—Bupropion—obesity	0.000173	0.00105	CcSEcCtD
Vandetanib—Anxiety—Orlistat—obesity	0.000172	0.00105	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000172	0.00105	CcSEcCtD
Vandetanib—Cough—Sibutramine—obesity	0.000172	0.00104	CcSEcCtD
Vandetanib—Malnutrition—Bupropion—obesity	0.000171	0.00104	CcSEcCtD
Vandetanib—Convulsion—Sibutramine—obesity	0.00017	0.00104	CcSEcCtD
Vandetanib—Blood creatinine increased—Topiramate—obesity	0.00017	0.00103	CcSEcCtD
Vandetanib—Hypertension—Sibutramine—obesity	0.00017	0.00103	CcSEcCtD
Vandetanib—Dry mouth—Orlistat—obesity	0.000169	0.00103	CcSEcCtD
Vandetanib—Dehydration—Topiramate—obesity	0.000169	0.00103	CcSEcCtD
Vandetanib—Dysgeusia—Bupropion—obesity	0.000168	0.00102	CcSEcCtD
Vandetanib—Chest pain—Sibutramine—obesity	0.000167	0.00102	CcSEcCtD
Vandetanib—Arthralgia—Sibutramine—obesity	0.000167	0.00102	CcSEcCtD
Vandetanib—Anxiety—Sibutramine—obesity	0.000167	0.00102	CcSEcCtD
Vandetanib—ALB—liver—obesity	0.000167	0.00151	CbGeAlD
Vandetanib—Oedema—Orlistat—obesity	0.000166	0.00101	CcSEcCtD
Vandetanib—Hypokalaemia—Topiramate—obesity	0.000165	0.001	CcSEcCtD
Vandetanib—Muscle spasms—Bupropion—obesity	0.000165	0.001	CcSEcCtD
Vandetanib—Infection—Orlistat—obesity	0.000165	0.001	CcSEcCtD
Vandetanib—Dry mouth—Sibutramine—obesity	0.000164	0.000996	CcSEcCtD
Vandetanib—ABCG2—pituitary gland—obesity	0.000163	0.00148	CbGeAlD
Vandetanib—Nervous system disorder—Orlistat—obesity	0.000163	0.00099	CcSEcCtD
Vandetanib—ABCG2—adipose tissue—obesity	0.000163	0.00147	CbGeAlD
Vandetanib—Nasopharyngitis—Topiramate—obesity	0.000162	0.000987	CcSEcCtD
Vandetanib—Vision blurred—Bupropion—obesity	0.000162	0.000983	CcSEcCtD
Vandetanib—Skin disorder—Orlistat—obesity	0.000161	0.00098	CcSEcCtD
Vandetanib—Tremor—Bupropion—obesity	0.000161	0.000978	CcSEcCtD
Vandetanib—Gastritis—Topiramate—obesity	0.000161	0.000977	CcSEcCtD
Vandetanib—Oedema—Sibutramine—obesity	0.000161	0.000977	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Topiramate—obesity	0.00016	0.000974	CcSEcCtD
Vandetanib—Infection—Sibutramine—obesity	0.000159	0.00097	CcSEcCtD
Vandetanib—Thrombocytopenia—Sibutramine—obesity	0.000157	0.000956	CcSEcCtD
Vandetanib—Dysphagia—Topiramate—obesity	0.000157	0.000954	CcSEcCtD
Vandetanib—Skin disorder—Sibutramine—obesity	0.000156	0.000949	CcSEcCtD
Vandetanib—Pancreatitis—Topiramate—obesity	0.000154	0.000935	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Orlistat—obesity	0.000151	0.00092	CcSEcCtD
Vandetanib—Bronchitis—Topiramate—obesity	0.000151	0.000917	CcSEcCtD
Vandetanib—Loss of consciousness—Bupropion—obesity	0.000151	0.000917	CcSEcCtD
Vandetanib—Insomnia—Orlistat—obesity	0.00015	0.000913	CcSEcCtD
Vandetanib—Cough—Bupropion—obesity	0.00015	0.00091	CcSEcCtD
Vandetanib—Paraesthesia—Orlistat—obesity	0.000149	0.000906	CcSEcCtD
Vandetanib—Gefitinib—ALB—obesity	0.000149	0.0483	CrCbGaD
Vandetanib—Convulsion—Bupropion—obesity	0.000149	0.000904	CcSEcCtD
Vandetanib—Hypertension—Bupropion—obesity	0.000148	0.000901	CcSEcCtD
Vandetanib—Dysuria—Topiramate—obesity	0.000147	0.000892	CcSEcCtD
Vandetanib—Neutropenia—Topiramate—obesity	0.000147	0.000892	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Sibutramine—obesity	0.000146	0.00089	CcSEcCtD
Vandetanib—Dyspepsia—Orlistat—obesity	0.000146	0.000888	CcSEcCtD
Vandetanib—Arthralgia—Bupropion—obesity	0.000146	0.000888	CcSEcCtD
Vandetanib—Chest pain—Bupropion—obesity	0.000146	0.000888	CcSEcCtD
Vandetanib—ABCG2—adrenal gland—obesity	0.000146	0.00132	CbGeAlD
Vandetanib—Upper respiratory tract infection—Topiramate—obesity	0.000146	0.000887	CcSEcCtD
Vandetanib—Anxiety—Bupropion—obesity	0.000145	0.000885	CcSEcCtD
Vandetanib—Insomnia—Sibutramine—obesity	0.000145	0.000883	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	0.000145	0.000882	CcSEcCtD
Vandetanib—Pollakiuria—Topiramate—obesity	0.000145	0.000881	CcSEcCtD
Vandetanib—Decreased appetite—Orlistat—obesity	0.000144	0.000877	CcSEcCtD
Vandetanib—Paraesthesia—Sibutramine—obesity	0.000144	0.000877	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Orlistat—obesity	0.000143	0.000871	CcSEcCtD
Vandetanib—Dyspnoea—Sibutramine—obesity	0.000143	0.000871	CcSEcCtD
Vandetanib—Photosensitivity reaction—Topiramate—obesity	0.000143	0.000871	CcSEcCtD
Vandetanib—Fatigue—Orlistat—obesity	0.000143	0.00087	CcSEcCtD
Vandetanib—Dry mouth—Bupropion—obesity	0.000143	0.000869	CcSEcCtD
Vandetanib—Weight decreased—Topiramate—obesity	0.000142	0.000863	CcSEcCtD
Vandetanib—Pain—Orlistat—obesity	0.000142	0.000863	CcSEcCtD
Vandetanib—Hyperglycaemia—Topiramate—obesity	0.000141	0.000861	CcSEcCtD
Vandetanib—Dyspepsia—Sibutramine—obesity	0.000141	0.00086	CcSEcCtD
Vandetanib—Pneumonia—Topiramate—obesity	0.000141	0.000856	CcSEcCtD
Vandetanib—Oedema—Bupropion—obesity	0.00014	0.000852	CcSEcCtD
Vandetanib—Infestation NOS—Topiramate—obesity	0.00014	0.000851	CcSEcCtD
Vandetanib—Infestation—Topiramate—obesity	0.00014	0.000851	CcSEcCtD
Vandetanib—Decreased appetite—Sibutramine—obesity	0.00014	0.000849	CcSEcCtD
Vandetanib—Depression—Topiramate—obesity	0.000139	0.000848	CcSEcCtD
Vandetanib—Infection—Bupropion—obesity	0.000139	0.000846	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Topiramate—obesity	0.000139	0.000843	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Sibutramine—obesity	0.000139	0.000843	CcSEcCtD
Vandetanib—ABCC1—liver—obesity	0.000138	0.00125	CbGeAlD
Vandetanib—Renal failure—Topiramate—obesity	0.000137	0.000836	CcSEcCtD
Vandetanib—Constipation—Sibutramine—obesity	0.000137	0.000835	CcSEcCtD
Vandetanib—Pain—Sibutramine—obesity	0.000137	0.000835	CcSEcCtD
Vandetanib—Nervous system disorder—Bupropion—obesity	0.000137	0.000835	CcSEcCtD
Vandetanib—Thrombocytopenia—Bupropion—obesity	0.000137	0.000834	CcSEcCtD
Vandetanib—Stomatitis—Topiramate—obesity	0.000136	0.000829	CcSEcCtD
Vandetanib—Skin disorder—Bupropion—obesity	0.000136	0.000827	CcSEcCtD
Vandetanib—Conjunctivitis—Topiramate—obesity	0.000136	0.000827	CcSEcCtD
Vandetanib—Urinary tract infection—Topiramate—obesity	0.000136	0.000827	CcSEcCtD
Vandetanib—Gastrointestinal pain—Orlistat—obesity	0.000136	0.000825	CcSEcCtD
Vandetanib—Haematuria—Topiramate—obesity	0.000133	0.000811	CcSEcCtD
Vandetanib—Epistaxis—Topiramate—obesity	0.000132	0.000802	CcSEcCtD
Vandetanib—Gastrointestinal pain—Sibutramine—obesity	0.000131	0.000799	CcSEcCtD
Vandetanib—Sinusitis—Topiramate—obesity	0.000131	0.000798	CcSEcCtD
Vandetanib—Abdominal pain—Orlistat—obesity	0.000131	0.000798	CcSEcCtD
Vandetanib—Body temperature increased—Orlistat—obesity	0.000131	0.000798	CcSEcCtD
Vandetanib—Bradycardia—Topiramate—obesity	0.000128	0.000777	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Bupropion—obesity	0.000128	0.000776	CcSEcCtD
Vandetanib—Abdominal pain—Sibutramine—obesity	0.000127	0.000772	CcSEcCtD
Vandetanib—Body temperature increased—Sibutramine—obesity	0.000127	0.000772	CcSEcCtD
Vandetanib—Insomnia—Bupropion—obesity	0.000127	0.00077	CcSEcCtD
Vandetanib—Haemoglobin—Topiramate—obesity	0.000126	0.000767	CcSEcCtD
Vandetanib—Paraesthesia—Bupropion—obesity	0.000126	0.000765	CcSEcCtD
Vandetanib—Haemorrhage—Topiramate—obesity	0.000126	0.000764	CcSEcCtD
Vandetanib—Dyspnoea—Bupropion—obesity	0.000125	0.000759	CcSEcCtD
Vandetanib—Urinary tract disorder—Topiramate—obesity	0.000124	0.000754	CcSEcCtD
Vandetanib—Dyspepsia—Bupropion—obesity	0.000123	0.00075	CcSEcCtD
Vandetanib—Urethral disorder—Topiramate—obesity	0.000123	0.000749	CcSEcCtD
Vandetanib—Decreased appetite—Bupropion—obesity	0.000122	0.00074	CcSEcCtD
Vandetanib—Visual impairment—Topiramate—obesity	0.000121	0.000736	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Bupropion—obesity	0.000121	0.000735	CcSEcCtD
Vandetanib—Fatigue—Bupropion—obesity	0.000121	0.000734	CcSEcCtD
Vandetanib—Pain—Bupropion—obesity	0.00012	0.000728	CcSEcCtD
Vandetanib—Constipation—Bupropion—obesity	0.00012	0.000728	CcSEcCtD
Vandetanib—Asthenia—Orlistat—obesity	0.000119	0.000724	CcSEcCtD
Vandetanib—Erythema multiforme—Topiramate—obesity	0.000119	0.000722	CcSEcCtD
Vandetanib—Pruritus—Orlistat—obesity	0.000117	0.000714	CcSEcCtD
Vandetanib—Eye disorder—Topiramate—obesity	0.000117	0.000714	CcSEcCtD
Vandetanib—Cardiac disorder—Topiramate—obesity	0.000116	0.000709	CcSEcCtD
Vandetanib—Asthenia—Sibutramine—obesity	0.000115	0.000701	CcSEcCtD
Vandetanib—Gastrointestinal pain—Bupropion—obesity	0.000114	0.000696	CcSEcCtD
Vandetanib—ABCG2—liver—obesity	0.000114	0.00103	CbGeAlD
Vandetanib—Angiopathy—Topiramate—obesity	0.000114	0.000693	CcSEcCtD
Vandetanib—Pruritus—Sibutramine—obesity	0.000114	0.000691	CcSEcCtD
Vandetanib—Diarrhoea—Orlistat—obesity	0.000114	0.000691	CcSEcCtD
Vandetanib—Mediastinal disorder—Topiramate—obesity	0.000113	0.000688	CcSEcCtD
Vandetanib—Alopecia—Topiramate—obesity	0.000111	0.000675	CcSEcCtD
Vandetanib—Body temperature increased—Bupropion—obesity	0.000111	0.000673	CcSEcCtD
Vandetanib—Abdominal pain—Bupropion—obesity	0.000111	0.000673	CcSEcCtD
Vandetanib—Mental disorder—Topiramate—obesity	0.00011	0.000669	CcSEcCtD
Vandetanib—Diarrhoea—Sibutramine—obesity	0.00011	0.000668	CcSEcCtD
Vandetanib—Dizziness—Orlistat—obesity	0.00011	0.000667	CcSEcCtD
Vandetanib—Malnutrition—Topiramate—obesity	0.000109	0.000665	CcSEcCtD
Vandetanib—Dysgeusia—Topiramate—obesity	0.000107	0.000651	CcSEcCtD
Vandetanib—CYP3A4—digestive system—obesity	0.000107	0.000966	CbGeAlD
Vandetanib—Dizziness—Sibutramine—obesity	0.000106	0.000646	CcSEcCtD
Vandetanib—Vomiting—Orlistat—obesity	0.000105	0.000642	CcSEcCtD
Vandetanib—Muscle spasms—Topiramate—obesity	0.000105	0.000639	CcSEcCtD
Vandetanib—Rash—Orlistat—obesity	0.000105	0.000636	CcSEcCtD
Vandetanib—Dermatitis—Orlistat—obesity	0.000105	0.000636	CcSEcCtD
Vandetanib—Headache—Orlistat—obesity	0.000104	0.000632	CcSEcCtD
Vandetanib—Vision blurred—Topiramate—obesity	0.000103	0.000626	CcSEcCtD
Vandetanib—Tremor—Topiramate—obesity	0.000102	0.000623	CcSEcCtD
Vandetanib—Vomiting—Sibutramine—obesity	0.000102	0.000621	CcSEcCtD
Vandetanib—Rash—Sibutramine—obesity	0.000101	0.000616	CcSEcCtD
Vandetanib—Dermatitis—Sibutramine—obesity	0.000101	0.000615	CcSEcCtD
Vandetanib—Headache—Sibutramine—obesity	0.000101	0.000612	CcSEcCtD
Vandetanib—Asthenia—Bupropion—obesity	0.0001	0.000611	CcSEcCtD
Vandetanib—Pruritus—Bupropion—obesity	9.9e-05	0.000602	CcSEcCtD
Vandetanib—Nausea—Orlistat—obesity	9.85e-05	0.000599	CcSEcCtD
Vandetanib—Loss of consciousness—Topiramate—obesity	9.6e-05	0.000584	CcSEcCtD
Vandetanib—Diarrhoea—Bupropion—obesity	9.58e-05	0.000583	CcSEcCtD
Vandetanib—Nausea—Sibutramine—obesity	9.54e-05	0.00058	CcSEcCtD
Vandetanib—Cough—Topiramate—obesity	9.53e-05	0.00058	CcSEcCtD
Vandetanib—Convulsion—Topiramate—obesity	9.47e-05	0.000576	CcSEcCtD
Vandetanib—Hypertension—Topiramate—obesity	9.43e-05	0.000574	CcSEcCtD
Vandetanib—Arthralgia—Topiramate—obesity	9.3e-05	0.000566	CcSEcCtD
Vandetanib—Chest pain—Topiramate—obesity	9.3e-05	0.000566	CcSEcCtD
Vandetanib—Anxiety—Topiramate—obesity	9.27e-05	0.000564	CcSEcCtD
Vandetanib—Dizziness—Bupropion—obesity	9.26e-05	0.000563	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	9.24e-05	0.000562	CcSEcCtD
Vandetanib—Dry mouth—Topiramate—obesity	9.1e-05	0.000553	CcSEcCtD
Vandetanib—Oedema—Topiramate—obesity	8.92e-05	0.000543	CcSEcCtD
Vandetanib—Vomiting—Bupropion—obesity	8.9e-05	0.000541	CcSEcCtD
Vandetanib—Infection—Topiramate—obesity	8.86e-05	0.000539	CcSEcCtD
Vandetanib—Rash—Bupropion—obesity	8.82e-05	0.000537	CcSEcCtD
Vandetanib—Dermatitis—Bupropion—obesity	8.82e-05	0.000536	CcSEcCtD
Vandetanib—CYP3A4—endocrine gland—obesity	8.81e-05	0.000799	CbGeAlD
Vandetanib—Headache—Bupropion—obesity	8.77e-05	0.000533	CcSEcCtD
Vandetanib—Nervous system disorder—Topiramate—obesity	8.74e-05	0.000532	CcSEcCtD
Vandetanib—Thrombocytopenia—Topiramate—obesity	8.73e-05	0.000531	CcSEcCtD
Vandetanib—Skin disorder—Topiramate—obesity	8.66e-05	0.000527	CcSEcCtD
Vandetanib—Nausea—Bupropion—obesity	8.31e-05	0.000506	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Topiramate—obesity	8.12e-05	0.000494	CcSEcCtD
Vandetanib—Insomnia—Topiramate—obesity	8.07e-05	0.000491	CcSEcCtD
Vandetanib—Paraesthesia—Topiramate—obesity	8.01e-05	0.000487	CcSEcCtD
Vandetanib—Dyspnoea—Topiramate—obesity	7.95e-05	0.000484	CcSEcCtD
Vandetanib—CYP3A4—liver—obesity	7.94e-05	0.00072	CbGeAlD
Vandetanib—Dyspepsia—Topiramate—obesity	7.85e-05	0.000478	CcSEcCtD
Vandetanib—Decreased appetite—Topiramate—obesity	7.75e-05	0.000472	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Topiramate—obesity	7.7e-05	0.000468	CcSEcCtD
Vandetanib—Fatigue—Topiramate—obesity	7.69e-05	0.000468	CcSEcCtD
Vandetanib—Constipation—Topiramate—obesity	7.63e-05	0.000464	CcSEcCtD
Vandetanib—Pain—Topiramate—obesity	7.63e-05	0.000464	CcSEcCtD
Vandetanib—Gastrointestinal pain—Topiramate—obesity	7.29e-05	0.000444	CcSEcCtD
Vandetanib—Abdominal pain—Topiramate—obesity	7.05e-05	0.000429	CcSEcCtD
Vandetanib—Body temperature increased—Topiramate—obesity	7.05e-05	0.000429	CcSEcCtD
Vandetanib—Asthenia—Topiramate—obesity	6.4e-05	0.000389	CcSEcCtD
Vandetanib—Pruritus—Topiramate—obesity	6.31e-05	0.000384	CcSEcCtD
Vandetanib—Diarrhoea—Topiramate—obesity	6.1e-05	0.000371	CcSEcCtD
Vandetanib—Dizziness—Topiramate—obesity	5.9e-05	0.000359	CcSEcCtD
Vandetanib—Vomiting—Topiramate—obesity	5.67e-05	0.000345	CcSEcCtD
Vandetanib—Rash—Topiramate—obesity	5.62e-05	0.000342	CcSEcCtD
Vandetanib—Dermatitis—Topiramate—obesity	5.62e-05	0.000342	CcSEcCtD
Vandetanib—Headache—Topiramate—obesity	5.59e-05	0.00034	CcSEcCtD
Vandetanib—Nausea—Topiramate—obesity	5.3e-05	0.000322	CcSEcCtD
Vandetanib—LYN—Signaling Pathways—MTOR—obesity	1.16e-06	5.93e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CB—obesity	1.16e-06	5.93e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MYC—obesity	1.15e-06	5.91e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCL2—obesity	1.15e-06	5.91e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—STAT3—obesity	1.15e-06	5.9e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TGFB1—obesity	1.15e-06	5.9e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—F2—obesity	1.15e-06	5.87e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PRKCB—obesity	1.15e-06	5.87e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—DPYD—obesity	1.14e-06	5.85e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GPX1—obesity	1.14e-06	5.85e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CB—obesity	1.14e-06	5.84e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MTOR—obesity	1.14e-06	5.84e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—STAT3—obesity	1.13e-06	5.81e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF1—obesity	1.13e-06	5.81e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT2—obesity	1.13e-06	5.8e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—BAD—obesity	1.13e-06	5.8e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CD—obesity	1.13e-06	5.79e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—PIK3CA—obesity	1.12e-06	5.73e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SERPINE1—obesity	1.12e-06	5.72e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MYC—obesity	1.11e-06	5.71e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—PIK3CA—obesity	1.11e-06	5.71e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TGFB1—obesity	1.11e-06	5.7e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CD36—obesity	1.11e-06	5.7e-06	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—AKT1—obesity	1.11e-06	5.69e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PRKAR2B—obesity	1.1e-06	5.63e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CB—obesity	1.1e-06	5.63e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—MAPK8—obesity	1.1e-06	5.63e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CG—obesity	1.1e-06	5.61e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—DCN—obesity	1.09e-06	5.59e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—PIK3CA—obesity	1.09e-06	5.59e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—PIK3CA—obesity	1.09e-06	5.58e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—obesity	1.09e-06	5.58e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CD—obesity	1.09e-06	5.58e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TYK2—obesity	1.09e-06	5.57e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—STAT3—obesity	1.09e-06	5.57e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—PIK3CA—obesity	1.09e-06	5.56e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IRS1—obesity	1.08e-06	5.55e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL6—obesity	1.08e-06	5.55e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—PIK3CA—obesity	1.08e-06	5.52e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RHOA—obesity	1.08e-06	5.52e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SERPINE1—obesity	1.08e-06	5.51e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—PIK3CA—obesity	1.07e-06	5.5e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MYC—obesity	1.07e-06	5.49e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TGFB1—obesity	1.07e-06	5.47e-06	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—AKT1—obesity	1.07e-06	5.46e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NOS3—obesity	1.07e-06	5.46e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3R1—obesity	1.07e-06	5.46e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CPT1A—obesity	1.06e-06	5.44e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MTHFR—obesity	1.05e-06	5.4e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TYK2—obesity	1.05e-06	5.36e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—STAT3—obesity	1.05e-06	5.36e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—POMC—obesity	1.04e-06	5.34e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NAMPT—obesity	1.04e-06	5.34e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RHOA—obesity	1.04e-06	5.32e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—INS—obesity	1.04e-06	5.32e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GCK—obesity	1.04e-06	5.3e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LIPC—obesity	1.04e-06	5.3e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARA—obesity	1.03e-06	5.29e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PIK3CA—obesity	1.03e-06	5.27e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOC3—obesity	1.03e-06	5.27e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3R1—obesity	1.03e-06	5.27e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NOS3—obesity	1.03e-06	5.27e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MMP9—obesity	1.03e-06	5.26e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCL2—obesity	1.02e-06	5.23e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—PIK3CA—obesity	1.02e-06	5.22e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—PIK3CA—obesity	1.02e-06	5.2e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—obesity	1.01e-06	5.17e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—TGFB1—obesity	1.01e-06	5.16e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MMP9—obesity	1.01e-06	5.15e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—STAT3—obesity	1e-06	5.14e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF1—obesity	1e-06	5.14e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT2—obesity	1e-06	5.14e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AGT—obesity	1e-06	5.13e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MAPK8—obesity	9.99e-07	5.12e-06	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—AKT1—obesity	9.99e-07	5.12e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CETP—obesity	9.99e-07	5.12e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—PIK3CA—obesity	9.92e-07	5.08e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MMP9—obesity	9.9e-07	5.07e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—obesity	9.9e-07	5.07e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SDC1—obesity	9.87e-07	5.06e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—obesity	9.87e-07	5.06e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MTOR—obesity	9.84e-07	5.04e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CB—obesity	9.84e-07	5.04e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOE—obesity	9.81e-07	5.02e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—PIK3CA—obesity	9.8e-07	5.02e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MAPK8—obesity	9.78e-07	5.01e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—obesity	9.73e-07	4.98e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CAV1—obesity	9.72e-07	4.98e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKR1C3—obesity	9.71e-07	4.98e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—TGFB1—obesity	9.71e-07	4.97e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—APOA1—obesity	9.7e-07	4.97e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—obesity	9.66e-07	4.95e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—obesity	9.65e-07	4.94e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CD—obesity	9.64e-07	4.94e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MAPK8—obesity	9.63e-07	4.93e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—obesity	9.62e-07	4.93e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SCARB1—obesity	9.56e-07	4.9e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—obesity	9.55e-07	4.89e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SERPINE1—obesity	9.53e-07	4.88e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—obesity	9.51e-07	4.87e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CB—obesity	9.49e-07	4.86e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MTOR—obesity	9.49e-07	4.86e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—PIK3CA—obesity	9.46e-07	4.85e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PIK3CA—obesity	9.28e-07	4.76e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SREBF1—obesity	9.28e-07	4.76e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—PIK3CA—obesity	9.28e-07	4.75e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TYK2—obesity	9.27e-07	4.75e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—obesity	9.27e-07	4.75e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RHOA—obesity	9.19e-07	4.71e-06	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—AKT1—obesity	9.14e-07	4.68e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—obesity	9.14e-07	4.68e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—obesity	9.11e-07	4.67e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—AKT1—obesity	9.11e-07	4.66e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3R1—obesity	9.1e-07	4.66e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NOS3—obesity	9.1e-07	4.66e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PIK3CA—obesity	9.09e-07	4.66e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GOT2—obesity	9.03e-07	4.63e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—obesity	9e-07	4.61e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—PIK3CA—obesity	8.95e-07	4.58e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—obesity	8.94e-07	4.58e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—AKT1—obesity	8.92e-07	4.57e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—AKT1—obesity	8.9e-07	4.56e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—AKT1—obesity	8.87e-07	4.55e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CG—obesity	8.85e-07	4.53e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—FASN—obesity	8.84e-07	4.53e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—AKT1—obesity	8.81e-07	4.51e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—obesity	8.81e-07	4.51e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—BCHE—obesity	8.8e-07	4.51e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—obesity	8.78e-07	4.5e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—AKT1—obesity	8.78e-07	4.5e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—obesity	8.67e-07	4.44e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—obesity	8.61e-07	4.41e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—TGFB1—obesity	8.59e-07	4.4e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—PIK3CA—obesity	8.57e-07	4.39e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MMP9—obesity	8.56e-07	4.38e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—obesity	8.54e-07	4.38e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP2E1—obesity	8.49e-07	4.35e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—obesity	8.49e-07	4.35e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TGFB1—obesity	8.47e-07	4.34e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—POMC—obesity	8.43e-07	4.32e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT1—obesity	8.41e-07	4.31e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MTOR—obesity	8.4e-07	4.3e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CB—obesity	8.4e-07	4.3e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NQO1—obesity	8.4e-07	4.3e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—obesity	8.38e-07	4.29e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—INS—obesity	8.38e-07	4.29e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT1—obesity	8.33e-07	4.27e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MAPK8—obesity	8.32e-07	4.26e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—obesity	8.31e-07	4.26e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT1—obesity	8.3e-07	4.25e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TGFB1—obesity	8.29e-07	4.25e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—PIK3CA—obesity	8.26e-07	4.23e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MMP9—obesity	8.25e-07	4.22e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—obesity	8.22e-07	4.21e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—obesity	8.18e-07	4.19e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TGFB1—obesity	8.16e-07	4.18e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT1—obesity	8.1e-07	4.15e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—obesity	8.05e-07	4.12e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC2A4—obesity	8.05e-07	4.12e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GCG—obesity	8.05e-07	4.12e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MAPK8—obesity	8.02e-07	4.11e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT1—obesity	8e-07	4.1e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYCS—obesity	7.94e-07	4.07e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—obesity	7.92e-07	4.06e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—PIK3CA—obesity	7.92e-07	4.06e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GOT1—obesity	7.8e-07	3.99e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GGT1—obesity	7.8e-07	3.99e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CD—obesity	7.78e-07	3.99e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT1—obesity	7.73e-07	3.96e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NCOA1—obesity	7.68e-07	3.93e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PIK3CA—obesity	7.61e-07	3.9e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—obesity	7.61e-07	3.9e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—obesity	7.59e-07	3.89e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT1—obesity	7.58e-07	3.88e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP19A1—obesity	7.57e-07	3.88e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—STK11—obesity	7.57e-07	3.88e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT1—obesity	7.43e-07	3.8e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NOS3—obesity	7.35e-07	3.76e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3R1—obesity	7.35e-07	3.76e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—obesity	7.33e-07	3.76e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—obesity	7.31e-07	3.75e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—PIK3CA—obesity	7.31e-07	3.75e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT1—obesity	7.31e-07	3.74e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MMP9—obesity	7.3e-07	3.74e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—PIK3CA—obesity	7.21e-07	3.69e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MAPK8—obesity	7.1e-07	3.64e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—obesity	7.07e-07	3.62e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—PIK3CA—obesity	7.06e-07	3.61e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TGFB1—obesity	7.05e-07	3.61e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—COMT—obesity	7.04e-07	3.6e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—obesity	7.01e-07	3.59e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT1—obesity	7e-07	3.59e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—PIK3CA—obesity	6.95e-07	3.56e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GNB3—obesity	6.94e-07	3.55e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARGC1A—obesity	6.94e-07	3.55e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMOX1—obesity	6.91e-07	3.54e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—obesity	6.81e-07	3.49e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TGFB1—obesity	6.8e-07	3.48e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CB—obesity	6.78e-07	3.47e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GNAS—obesity	6.75e-07	3.46e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT1—obesity	6.75e-07	3.46e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—obesity	6.72e-07	3.44e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PIK3CA—obesity	6.7e-07	3.43e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOB—obesity	6.61e-07	3.39e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—obesity	6.49e-07	3.32e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—obesity	6.47e-07	3.32e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT1—obesity	6.47e-07	3.31e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—obesity	6.38e-07	3.27e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LPL—obesity	6.32e-07	3.24e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—obesity	6.25e-07	3.2e-06	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—AKT1—obesity	6.22e-07	3.19e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GPX1—obesity	6.16e-07	3.16e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—obesity	6.15e-07	3.15e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—obesity	6.03e-07	3.09e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TGFB1—obesity	6.02e-07	3.08e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CD36—obesity	6e-07	3.07e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PIK3CA—obesity	6e-07	3.07e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT1—obesity	5.97e-07	3.06e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT1—obesity	5.89e-07	3.02e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PIK3CA—obesity	5.78e-07	2.96e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT1—obesity	5.76e-07	2.95e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—obesity	5.69e-07	2.91e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT1—obesity	5.67e-07	2.91e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARA—obesity	5.58e-07	2.86e-06	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—AKT1—obesity	5.47e-07	2.8e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AGT—obesity	5.4e-07	2.77e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—obesity	5.31e-07	2.72e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOE—obesity	5.29e-07	2.71e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CAV1—obesity	5.25e-07	2.69e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—APOA1—obesity	5.23e-07	2.68e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—obesity	5.12e-07	2.62e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PIK3CA—obesity	5.12e-07	2.62e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT1—obesity	4.9e-07	2.51e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CG—obesity	4.78e-07	2.45e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT1—obesity	4.72e-07	2.42e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—obesity	4.61e-07	2.36e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—POMC—obesity	4.55e-07	2.33e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—obesity	4.53e-07	2.32e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—INS—obesity	4.52e-07	2.32e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CD—obesity	4.2e-07	2.15e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT1—obesity	4.18e-07	2.14e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—obesity	4.15e-07	2.12e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PIK3CA—obesity	4.13e-07	2.12e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3R1—obesity	3.97e-07	2.03e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NOS3—obesity	3.97e-07	2.03e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CB—obesity	3.66e-07	1.88e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—obesity	3.63e-07	1.86e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKT1—obesity	3.38e-07	1.73e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PIK3CA—obesity	2.23e-07	1.14e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKT1—obesity	1.82e-07	9.34e-07	CbGpPWpGaD
